FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1725-1730 December 2, 1999 Number 23 Next

Abstract PDF Editorial by Hunsicker, L. G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The extent to which renal allotransplantation — as compared with long-term dialysis — improves survival among patients with end-stage renal disease is controversial, because those selected for transplantation may have a lower base-line risk of death.

Methods In an attempt to distinguish the effects of patient selection from those of transplantation itself, we conducted a longitudinal study of mortality in 228,552 patients who were receiving long-term dialysis for end-stage renal disease. Of these patients, 46,164 were placed on a waiting list for transplantation, 23,275 of whom received a first cadaveric transplant between 1991 and 1997. The relative risk of death and survival were assessed with time-dependent nonproportional-hazards analysis, with adjustment for age, race, sex, cause of end-stage renal disease, geographic region, time from first treatment for end-stage renal disease to placement on the waiting list, and year of initial placement on the list.

Results Among the various subgroups, the standardized mortality ratio for the patients on dialysis who were awaiting transplantation (annual death rate, 6.3 per 100 patient-years) was 38 to 58 percent lower than that for all patients on dialysis (annual death rate, 16.1 per 100 patient-years). The relative risk of death during the first 2 weeks after transplantation was 2.8 times as high as that for patients on dialysis who had equal lengths of follow-up since placement on the waiting list, but at 18 months the risk was much lower (relative risk, 0.32; 95 percent confidence interval, 0.30 to 0.35; P<0.001). The likelihood of survival became equal in the two groups within 5 to 673 days after transplantation in all the subgroups of patients we examined. The long-term mortality rate was 48 to 82 percent lower among transplant recipients (annual death rate, 3.8 per 100 patient-years) than patients on the waiting list, with relatively larger benefits among patients who were 20 to 39 years old, white patients, and younger patients with diabetes.

Conclusions Among patients with end-stage renal disease, healthier patients are placed on the waiting list for transplantation, and long-term survival is better among those on the waiting list who eventually undergo transplantation.

The number of cadaveric organs available has not kept up with the increasing number of patients awaiting transplantation.¹¹ The rapid expansion of the recipient pool, particularly of high-risk patients, has increased the pressure on transplantation programs to devise appropriate selection criteria (e.g., age) to optimize the use of scarce organs. The present study was designed to compare survival of patients undergoing transplantation with survival of those awaiting transplantation.

Methods

We used data from the U.S. Renal Data System for this study. From 1991 through 1996, 252,358 patients under the age of 70 years began treatment for end-stage renal disease in the United States. We excluded patients who were 70 years of age or older, because only about 1 percent of them received a cadaveric renal transplant; those whose race was listed as other than Asian, Native American, black, or white; and those for whom the cause of end-stage renal disease or the region they were from was not reported. Patients who received transplants without first undergoing dialysis were also excluded. The resulting study population included 228,552 patients, of whom 46,164 had been placed on the waiting list for transplantation for the first time. Among these patients on the waiting list, 23,275 received a first cadaveric transplant by December 31, 1997.

Survival was analyzed as the time from initial placement on the waiting list to death, with data censored at the time of receipt of a first transplant from a living donor or on December 31, 1997. A time-dependent, nonproportional-hazards analysis was used to account for the fact that patients switched from the dialysis group to the transplantation group during follow-up. The analysis showed that mortality was higher in the transplantation group immediately after transplantation and then dropped below the rate in the dialysis group over the long term. We calculated the number of days between placement on the waiting list and the time at which the death rates became equal in the two groups as well as cumulative survival probabilities and the projected years of life, with adjustment for the time spent on the waiting list.¹² The analyses were adjusted for age, race, sex, cause of end-stage renal disease (glomerulonephritis, diabetes, or other causes), year of placement on the waiting list, time from first treatment for end-stage renal disease to placement on the waiting list, and geographic region. The analysis was conducted according to the intention to treat; therefore, patients were not dropped from the analysis if they were removed from the waiting list or if transplantation failed. Although some patients were on the waiting list at multiple centers and received more than one transplant, we only considered the time of the initial placement on the waiting list and the first transplantation. We analyzed subgroups of patients separately. In addition, we calculated standardized mortality ratios, adjusted for age, sex, race, and diabetes as the cause of end-stage renal disease,¹³ to compare the death rates among the 46,164 patients on dialysis who were placed on the waiting list and the 23,275 recipients of cadaveric transplants with those among the entire group of 228,552 patients on dialysis; we used the death-rate tables of the U.S. Renal Data System for all U.S. patients on dialysis in 1997 as a reference.¹¹

Results

The percentages of blacks, Native Americans, women, and patients with diabetes were lower among patients who had been placed on the waiting list and recipients of cadaveric transplants than among the group of patients on dialysis as a whole (Table 1). The unadjusted annual death rates per 100 patient-years at risk for all patients on dialysis, patients on the waiting list, and transplant recipients were 16.1, 6.3, and 3.8, respectively (Table 2). The annual death rate for all patients on dialysis was 2.6 times as high as that for patients on the waiting list, and the annual death rate for patients on the waiting list was 1.7 times as high as that for transplant recipients. The total deaths in each group are also shown in Table 2.

View this table: [in this window] [in a new window]   Table 1. Characteristics of Patients with End-Stage Renal Disease, 1991–1997.

 

View this table: [in this window] [in a new window]   Table 2. Annual Death Rates and Total Numbers of Deaths, 1991–1997.

 
The standardized mortality ratios, adjusted for age, race, sex, and diabetes as the cause of end-stage renal disease, for patients on the waiting list as compared with the corresponding group of all patients on dialysis who were younger than 70 years at the onset of end-stage renal disease (relative risk, 1.0) are shown in Figure 1.¹³ The standardized mortality ratio was 49 percent lower (relative risk, 0.51; 95 percent confidence interval, 0.49 to 0.53; P<0.001) among patients on the waiting list and 69 percent lower (data not shown) among the recipients of cadaveric transplants. Thus, much of the large reduction in risk among the recipients of cadaveric transplants was most likely due to the selection of healthier patients for placement on the waiting list. The standardized mortality ratio was also significantly lower among each subgroup of patients on the waiting list (whites, blacks, Asians, Native Americans, female patients, male patients, those with diabetes, and those without diabetes) than among the corresponding subgroup of all patients on dialysis (P<0.001 for each comparison).

View larger version (8K): [in this window] [in a new window]   Figure 1. Standardized Mortality Ratios for Patients on the Waiting List for Renal Transplants, According to Race, Sex, and Diabetes as the Cause of End-Stage Renal Disease (ESRD), 1991–1997. The reference groups were all patients on dialysis who were less than 70 years of age at the onset of end-stage renal disease and the corresponding subgroups classified according to race, sex, and diabetes as the cause of end-stage renal disease (relative risk of death, 1.0). The ratios were adjusted for age, race, sex, and diabetes as the cause of end-stage renal disease. I bars indicate 95 percent confidence intervals. P<0.001 for all comparisons.

 
The relative risk of death among transplant recipients, as compared with patients on the waiting list, adjusted for age, sex, race, cause of end-stage renal disease, year of placement on the waiting list, and time from first treatment for end-stage renal disease to placement on the waiting list, is shown in Figure 2. Transplant recipients, including patients in whom transplantation was unsuccessful, were compared with patients on the waiting list who had equal lengths of follow-up since placement on the waiting list but who had not yet received a cadaveric transplant. The risk of death among the transplant recipients during the first 2 weeks after transplantation was 2.8 times as high as that among the patients on the waiting list and remained elevated until 106 days after transplantation. After this time, the risk was lower among the transplant recipients, but the likelihood of survival did not become equal in the two groups until day 244, because of the initially higher risk among the transplant recipients. The long-term mortality risk for the transplant recipients was estimated to be 68 percent lower than that of the patients on the waiting list (relative risk, 0.32; 95 percent confidence interval, 0.30 to 0.35; P<0.001). The long-term risk was estimated on the basis of three to four years of follow-up.

View larger version (4K): [in this window] [in a new window]   Figure 2. Adjusted Relative Risk of Death among 23,275 Recipients of a First Cadaveric Transplant. The reference group was the 46,164 patients on dialysis who were on the waiting list (relative risk, 1.0). Patients in both groups had equal lengths of follow-up since placement on the waiting list. Values were adjusted for age, sex, race, cause of end-stage renal disease, year of placement on the waiting list, geographic region, and time from first treatment for end-stage renal disease to placement on the waiting list. The points at which the risk of death and the likelihood of survival were equal in the two groups are indicated. A log scale was used.

 
The outcomes among the various subgroups of patients who received a cadaveric transplant are shown in Table 3. Overall, the projected years of life remaining were 10 for patients who remained on the waiting list and 20 for those who received a transplant. The greatest difference in long-term survival was found among patients who were 20 to 39 years old at the time of placement on the waiting list: those who underwent transplantation were projected to live almost 17 years longer than those who remained on the waiting list. Among the patients who were 60 to 74 years old, the cumulative survival rate improved after the first year after transplantation, with a projected increase in the life span of four years and a decrease in the long-term risk of death of 61 percent. When this subgroup was further subdivided into patients who were 60 to 64 years of age, those who were 65 to 69 years, and those who were 70 to 74 years, the projected increases in the life span were 4.3 years, 2.8 years, and 1.0 year, respectively. When the results were analyzed according to race, transplantation reduced the long-term relative risk of death more among Asians and whites than among Native Americans and blacks. However, in all four racial groups, transplantation significantly reduced the long-term risk of death, with initially higher mortality in the transplantation groups disappearing within less than half a year. The cumulative mortality rate was lower within 10 months after transplantation in all racial groups except Asians, who had the lowest mortality rate while receiving dialysis on the waiting list and for whom it required two years after transplantation for the mortality rate to return to this level.

View this table: [in this window] [in a new window]   Table 3. Outcome among Recipients of First Cadaveric Transplants, According to Characteristics at the Time of Initial Placement on the Waiting List, 1991–1997.

 
The relative survival benefits of transplantation were similar for men and women, with the long-term risk of death decreasing by 66 percent and 70 percent, respectively, and the initially higher mortality disappearing within eight and seven months, respectively. The results were similar for the subgroups of patients with diabetes, glomerulonephritis, and other causes of end-stage renal disease. Among patients with diabetes who were on the waiting list, the annual mortality rate was close to 11 percent. Transplantation reduced the risk of death by 73 percent (relative risk, 0.27; 95 percent confidence interval, 0.24 to 0.30; P<0.001). When projected long-term survival after transplantation was analyzed according to the cause of end-stage renal disease, the greatest increase occurred among patients with diabetes, with a gain of more than 11 years, as compared with an increase of 7 years among those with glomerulonephritis and 8 years among those with other causes of end-stage renal disease.

Patients with diabetes and patients who were 20 to 39 years old, 40 to 59 years old, or 60 to 74 years old at the time of placement on the waiting list were examined to assess the benefit of current practices of transplantation in these subgroups. In all these subgroups, transplantation reduced long-term mortality by over 50 percent (relative risk, <0.50; P<0.001). In all three age groups, the projected increase in the life span after transplantation was greater among patients with diabetes than among those without diabetes.

Discussion

Our findings document that there is substantial selection of healthier patients for placement on the waiting list for transplantation. The magnitude of this bias is similar to that reported previously.¹⁴ The mortality rate for the patients on dialysis who were on the waiting list was about half that of all patients on dialysis when subgroups were analyzed according to age, sex, race, and cause of end-stage renal disease. Thus, studies that compared the outcome among patients who received transplants with that among all patients on dialysis were biased in favor of the former group, because high-risk patients on dialysis who were not candidates for transplantation were included in the reference group. We avoided this selection bias, and we still found large long-term benefits for cadaveric transplantation, despite the increased short-term risk of death after transplantation. Our results also demonstrate that transplantation improved longevity in all groups of recipients, including patients who were 60 to 74 years old at the time of transplantation.

Comparing survival among transplant recipients with that among all patients on dialysis who had been on the waiting list for the same length of time but who had not yet undergone transplantation minimized the time-to-treatment bias. We found that the relative risk of death among recipients of a first cadaveric renal transplant relative to that among patients on the waiting list varies substantially with time. The risk was initially increased. This finding was not unexpected and most likely relates to risks associated with the surgery itself and to the use of high-dose immunosuppressive therapy. The subsequent decrease in the risk of death counterbalanced the initially high rates and resulted in a cumulative survival benefit beginning 244 days after transplantation overall. The long-term reduction in the risk of death was large for all subgroups of patients, averaging 66 percent, as compared with the risk of death among corresponding patients on the waiting list of the same age, sex, and race and with the same cause of end-stage renal disease. Since post-transplantation mortality was assessed independently of allograft function according to an intention-to-treat analysis, this information can be used to advise patients. This approach and methodology have previously been used in a regional registry.^12,14,15 Adjustments for the year of placement on the waiting list and the interval between placement on the list and transplantation minimize the potential effects of an improvement in outcomes over time. Such an improvement has been documented for both patients on dialysis^11,16 and transplant recipients.^11,17

A major reduction in the relative risk of death does not in itself indicate the extent of the increase in life span. The latter depends on both the death rate and the relative risk. We assessed both clinically relevant measures. The projected increase in life span conferred by transplantation was 10 years overall and ranged from 3 to 17 years according to patient group. The larger estimates need to be viewed with greater caution than the shorter estimates, because the values are extrapolations. Furthermore, both short-term survival and long-term survival have been improving for patients on dialysis and transplant recipients in recent years,¹¹ and this could also affect the results. In addition, the use of transplants from living donors, which we did not study, should be encouraged, since it has a better outcome than cadaveric transplantation.^18,19

Our use of the intention-to-treat analysis allows an approximate comparison of transplant recipients with candidates for transplantation who have been on the waiting list for the same length of time. Since patients were enrolled in the study at the time of initial placement on the waiting list, these results can be used to answer questions regarding the risks and benefits of cadaveric renal transplantation as of the time of placement on the list. Assessment of the risks and benefits of transplantation on the day that an organ becomes available would require complete and reliable data on temporary and permanent removal from the waiting list.²⁰ Removing patients from the analysis at the time of removal from the waiting list would yield a biased result, as is clear from an analysis of the result after the removal of all patients on the waiting list just before death. The latter approach would cause the death rate among patients on the waiting list to be zero, a biased estimate.

Our analysis of U.S. data demonstrates that the patients on dialysis who were placed on the waiting list for transplantation were those with a markedly better likelihood of survival. Recipients of a first cadaveric renal transplant had an initially higher risk of death than those who remained on dialysis but a subsequent long-term benefit. Elderly patients also benefited from transplantation, although the survival benefit was less than that for younger patients.

Supported by a grant from National Institute of Diabetes and Digestive and Kidney Diseases (NO1-DK-3-2202).

Source Information

From the U.S. Renal Data System Coordinating Center (R.A.W., V.B.A.) and the Departments of Biostatistics (R.A.W., V.B.A.), Internal Medicine (A.O.O., F.K.P.), and Epidemiology (F.K.P.), University of Michigan, Ann Arbor; Brigham and Women's Hospital, Boston (E.L.M.); the Department of Pediatric Nephrology, University of California Los Angeles, Los Angeles (R.E.E.); the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md. (L.Y.C.A.); and the University Renal Research Education Association, Ann Arbor, Mich. (P.J.H.).

Address reprint requests to Dr. Wolfe at the University of Michigan, 315 W. Huron, Suite 240, Ann Arbor, MI 48103, or at bobwolfe{at}umich.edu.

References

1. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-559. [Abstract]
2. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-242. [Medline]
3. Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation -- a prospective study. Transplantation 1992;54:656-660. [Medline]
4. Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation. I. The impact of dialysis pre-transplant. Kidney Int 1998;53:767-772. [CrossRef][Medline]
5. Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA. Patient survival after renal transplantation: more than 25 years follow-up. Nephrol Dial Transplant 1997;12:1672-1679. [Free Full Text]
6. Schaubel D, Desmeules M, Mao Y, Jeffery J, Fenton S. Survival experience among elderly end-stage renal disease patients: a controlled comparison of transplantation and dialysis. Transplantation 1995;60:1389-1394. [Medline]
7. Weller JM, Port FK, Swartz RD, Ferguson CW, Williams GW, Jacobs JF Jr. Analysis of survival of end-stage renal disease patients. Kidney Int 1982;21:78-83. [Medline]
8. Gaylin DS, Held PJ, Port FK, et al. The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA 1993;269:603-608. [Free Full Text]
9. Held PJ, Pauly MV, Bovbjerg RR, Newmann J, Salvatierra O Jr. Access to kidney transplantation: has the United States eliminated income and racial differences? Arch Intern Med 1988;148:2594-2600. [Free Full Text]
10. Kasiske BL, London W, Ellison MD. Race and socioeconomic factors influencing early placement on the kidney transplant waiting list. J Am Soc Nephrol 1998;9:2142-2147. [Abstract]
11. Renal Data System. USRDS 1999 annual data report. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, April 1999. (See http://www.med.umich.edu/usrds/.)
12. Mauger EA, Wolfe RA, Port FK. Transient effects in the Cox proportional hazards regression model. Stat Med 1995;14:1553-1565. [Medline]
13. Wolfe RA, Gaylin DS, Port FK, Held PJ, Wood CL. Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int 1992;42:991-996. [Medline]
14. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993;270:1339-1343. [Free Full Text]
15. Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994;24:59-64. [Medline]
16. Wolfe RA, Held PJ, Hulbert-Shearon TE, Agodoa LYC, Port FK. A critical examination of trends in outcomes over the last decade. Am J Kidney Dis 1998;32:Suppl 4:S9-S15. [Medline]
17. Cecka JM. The UNOS Scientific Renal Transplant Registry — ten years of kidney transplants. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1997. Los Angeles: UCLA Tissue Typing Laboratory, 1998:1-14.
18. Ojo AO, Port FK, Mauger EA, Wolfe RA, Leichtman AB. Relative impact of donor type on renal allograft survival in black and white recipients. Am J Kidney Dis 1995;25:623-628. [Medline]
19. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333-336. [Free Full Text]
20. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998;9:2135-2141. [Abstract]

Abstract PDF Editorial by Hunsicker, L. G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Mortality among Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Transplant Recipients
Gatchalian R. A., Leehey D. J., Wolfe R. A., Ashby V. B., Port F. K.
Extract | Full Text  
N Engl J Med 2000; 342:893-894, Mar 23, 2000. Correspondence

This article has been cited by other articles:

• Da Rocha, M., Zarka, Z. A., Riambau, V. A. (2009). Endovascular treatment of thoracic aortic pathology in renal transplant recipients: early and intermediate-term results. ICVTS 9: 947-950 [Abstract] [Full Text]  
• Gonzalez-Posada, J. M., Marrero, D., Hernandez, D., Coll, E., Perez Tamajon, L., Gutierrez, P., Martin, E., Bravo, A., Alarco, A., Matesanz, R. (2009). Pancreas transplantation: differences in activity between Europe and the United States. Nephrol Dial Transplant 0: gfp594v1-gfp594 [Abstract] [Full Text]  
• Al-Mallah, M. H., Hachamovitch, R., Dorbala, S., Di Carli, M. F. (2009). Incremental Prognostic Value of Myocardial Perfusion Imaging in Patients Referred to Stress Single-Photon Emission Computed Tomography With Renal Dysfunction. Circ Cardiovasc Imaging 2: 429-436 [Abstract] [Full Text]  
• Etter, C., Straub, Y., Hersberger, M., Raz, H. R., Kistler, T., Kiss, D., Wuthrich, R. P., Gloor, H.-J., Aerne, D., Wahl, P., Klaghofer, R., Ambuhl, P. M. (2009). Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis. Eur Heart J 0: ehp429v1-ehp429 [Abstract] [Full Text]  
• Bayat, S., Kessler, M., Briancon, S., Frimat, L. (2009). Survival of transplanted and dialysed patients in a French region with focus on outcomes in the elderly. Nephrol Dial Transplant 0: gfp469v1-gfp469 [Abstract] [Full Text]  
• Pauly, R. P., Gill, J. S., Rose, C. L., Asad, R. A., Chery, A., Pierratos, A., Chan, C. T. (2009). Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 24: 2915-2919 [Abstract] [Full Text]  
• Quintana, L. F., Campistol, J. M., Alcolea, M. P., Banon-Maneus, E., Sol-Gonzalez, A., Cutillas, P. R. (2009). Application of Label-free Quantitative Peptidomics for the Identification of Urinary Biomarkers of Kidney Chronic Allograft Dysfunction. Mol. Cell. Proteomics 8: 1658-1673 [Abstract] [Full Text]  
• Schold, J., Srinivas, T. R., Sehgal, A. R., Meier-Kriesche, H.-U. (2009). Half of Kidney Transplant Candidates Who Are Older than 60 Years Now Placed on the Waiting List Will Die before Receiving a Deceased-Donor Transplant. CJASN 4: 1239-1245 [Abstract] [Full Text]  
• Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E. (2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol 53: 2129-2140 [Abstract] [Full Text]  
• Hagstrom, E., Hellman, P., Larsson, T. E., Ingelsson, E., Berglund, L., Sundstrom, J., Melhus, H., Held, C., Lind, L., Michaelsson, K., Arnlov, J. (2009). Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community. Circulation 119: 2765-2771 [Abstract] [Full Text]  
• Kolonko, A., Chudek, J., Wicek, A. (2009). Prediction of the severity and outcome of acute tubular necrosis based on continuity of Doppler spectrum in the early period after kidney transplantation. Nephrol Dial Transplant 24: 1631-1635 [Abstract] [Full Text]  
• Tonelli, M., Klarenbach, S., Rose, C., Wiebe, N., Gill, J. (2009). Access to Kidney Transplantation Among Remote- and Rural-Dwelling Patients With Kidney Failure in the United States. JAMA 301: 1681-1690 [Abstract] [Full Text]  
• Gordon, E. J., Caicedo, J. C. (2009). Ethnic advantages in kidney transplant outcomes: the Hispanic Paradox at work?. Nephrol Dial Transplant 24: 1103-1109 [Full Text]  
• Young, B. Y., Gill, J., Huang, E., Takemoto, S. K., Anastasi, B., Shah, T., Bunnapradist, S. (2009). Living Donor Kidney Versus Simultaneous Pancreas-Kidney Transplant in Type I Diabetics: An Analysis of the OPTN/UNOS Database. CJASN 4: 845-852 [Abstract] [Full Text]  
• Hartmann, E. L., Kitzman, D., Rocco, M., Leng, X., Klepin, H., Gordon, M., Rejeski, J., Berry, M., Kritchevsky, S. (2009). Physical Function in Older Candidates for Renal Transplantation: An Impaired Population. CJASN 4: 588-594 [Abstract] [Full Text]  
• Vamos, E. P., Csepanyi, G., Zambo, M., Molnar, M. Z., Rethelyi, J., Kovacs, A., Marton, A., Nemeth, Z., Novak, M., Mucsi, I. (2009). Sociodemographic factors and patient perceptions are associated with attitudes to kidney transplantation among haemodialysis patients. Nephrol Dial Transplant 24: 653-660 [Abstract] [Full Text]  
• Quintana, L. F., Sole-Gonzalez, A., Kalko, S. G., Banon-Maneus, E., Sole, M., Diekmann, F., Gutierrez-Dalmau, A., Abian, J., Campistol, J. M. (2009). Urine Proteomics to Detect Biomarkers for Chronic Allograft Dysfunction. J. Am. Soc. Nephrol. 20: 428-435 [Abstract] [Full Text]  
• Galliford, J, Game, D S (2009). Modern renal transplantation: present challenges and future prospects. Postgrad. Med. J. 85: 91-101 [Abstract] [Full Text]  
• Gaston, R. S. (2009). Must Health Literacy Be a Prerequisite for Kidney Transplantation?. CJASN 4: 16-17 [Full Text]  
• Grubbs, V., Gregorich, S. E., Perez-Stable, E. J., Hsu, C.-y. (2009). Health Literacy and Access to Kidney Transplantation. CJASN 4: 195-200 [Abstract] [Full Text]  
• Giessing, M., Fuller, T. F., Friedersdorff, F., Deger, S., Wille, A., Neumayer, H.-H., Schmidt, D., Budde, K., Liefeldt, L. (2009). Outcomes of Transplanting Deceased-Donor Kidneys between Elderly Donors and Recipients. J. Am. Soc. Nephrol. 20: 37-40 [Abstract] [Full Text]  
• Perico, N., Cattaneo, D., Bikbov, B., Remuzzi, G. (2009). Hepatitis C Infection and Chronic Renal Diseases. CJASN 4: 207-220 [Abstract] [Full Text]  
• Courtney, A.E., McNamee, P.T., Maxwell, A.P. (2008). The evolution of renal transplantation in clinical practice: for better, for worse?. QJM 101: 967-978 [Abstract] [Full Text]  
• O'Callaghan, C.A. (2008). Kidney transplantation--the long term view. QJM 101: 985-986 [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Patel, R. K., Mark, P. B., Johnston, N., McGregor, E., Dargie, H. J., Jardine, A. G. (2008). Renal Transplantation Is Not Associated with Regression of Left Ventricular Hypertrophy: A Magnetic Resonance Study. CJASN 3: 1807-1811 [Abstract] [Full Text]  
• Gourishankar, S., Courtney, M., Jhangri, G. S., Cembrowski, G., Pannu, N. (2008). Serum cystatin C performs similarly to traditional markers of kidney function in the evaluation of donor kidney function prior to and following unilateral nephrectomy. Nephrol Dial Transplant 23: 3004-3009 [Abstract] [Full Text]  
• Earnshaw, S. R., Graham, C. N., Irish, W. D., Sato, R., Schnitzler, M. A. (2008). Lifetime Cost-Effectiveness of Calcineurin Inhibitor Withdrawal After De Novo Renal Transplantation. J. Am. Soc. Nephrol. 19: 1807-1816 [Abstract] [Full Text]  
• Chisholm-Burns, M. A., Kwong, W. J., Mulloy, L. L., Spivey, C. A. (2008). Nonmodifiable characteristics associated with nonadherence to immunosuppressant therapy in renal transplant recipients. Am J Health Syst Pharm 65: 1242-1247 [Abstract] [Full Text]  
• Shroff, G. R., Skeans, M., Herzog, C. A. (2008). Outcomes of renal transplant and waiting list patients with bacterial endocarditis in the United States. Nephrol Dial Transplant 23: 2381-2385 [Abstract] [Full Text]  
• Haneuse, S. J.-P. A., Rudser, K. D., Gillen, D. L. (2008). The separation of timescales in Bayesian survival modeling of the time-varying effect of a time-dependent exposure. Biostatistics 9: 400-410 [Abstract] [Full Text]  
• Reese, P. P., Shea, J. A., Berns, J. S., Simon, M. K., Joffe, M. M., Bloom, R. D., Feldman, H. I. (2008). Recruitment of Live Donors by Candidates for Kidney Transplantation. CJASN 3: 1152-1159 [Abstract] [Full Text]  
• Matas, A. J (2008). Should we pay donors to increase the supply of organs for transplantation? Yes. BMJ 336: 1342-1342 [Full Text]  
• Saudan, P., Kossovsky, M., Halabi, G., Martin, P. Y., Perneger, T. V., for the Western Switzerland Dialysis Study Group, (2008). Quality of care and survival of haemodialysed patients in western Switzerland. Nephrol Dial Transplant 23: 1975-1981 [Abstract] [Full Text]  
• Schaeffner, E. S., Kurth, T., Bowman, T. S., Gelber, R. P., Gaziano, J. M. (2008). Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant 23: 1246-1251 [Abstract] [Full Text]  
• Aull-Watschinger, S., Konstantin, H., Demetriou, D., Schillinger, M., Habicht, A., Horl, W. H., Watschinger, B. (2008). Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant 23: 1429-1435 [Abstract] [Full Text]  
• Delahousse, M., Chaignon, M., Mesnard, L., Boutouyrie, P., Safar, M. E., Lebret, T., Pastural-Thaunat, M., Tricot, L., Kolko-Labadens, A., Karras, A., Haymann, J.-P. (2008). Aortic Stiffness of Kidney Transplant Recipients Correlates with Donor Age. J. Am. Soc. Nephrol. 19: 798-805 [Abstract] [Full Text]  
• Li, G., Xu, J., Wang, P., Velazquez, H., Li, Y., Wu, Y., Desir, G. V. (2008). Catecholamines Regulate the Activity, Secretion, and Synthesis of Renalase. Circulation 117: 1277-1282 [Abstract] [Full Text]  
• Dilworth, M. R., Clancy, M. J., Marshall, D., Bravery, C. A., Brenchley, P. E., Ashton, N. (2008). Development and functional capacity of transplanted rat metanephroi. Nephrol Dial Transplant 23: 871-879 [Abstract] [Full Text]  
• Heldal, K., Leivestad, T., Hartmann, A., Svendsen, M. V., Lien, B. H., Midtvedt, K. (2008). Kidney transplantation in the elderly--the Norwegian experience. Nephrol Dial Transplant 23: 1026-1031 [Abstract] [Full Text]  
• Abecassis, M., Bartlett, S. T., Collins, A. J., Davis, C. L., Delmonico, F. L., Friedewald, J. J., Hays, R., Howard, A., Jones, E., Leichtman, A. B., Merion, R. M., Metzger, R. A., Pradel, F., Schweitzer, E. J., Velez, R. L., Gaston, R. S. (2008). Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) Conference. CJASN 3: 471-480 [Abstract] [Full Text]  
• Srinivas, T. R., Meier-Kriesche, H.-U. (2008). Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects: Objectives and Interim Result. CJASN 3: S101-S116 [Abstract] [Full Text]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• Axelrod, D. A., Guidinger, M. K., Finlayson, S., Schaubel, D. E., Goodman, D. C., Chobanian, M., Merion, R. M. (2008). Rates of Solid-Organ Wait-listing, Transplantation, and Survival Among Residents of Rural and Urban Areas. JAMA 299: 202-207 [Abstract] [Full Text]  
• Knoll, G. A., Cantarovitch, M., Cole, E., Gill, J., Gourishankar, S., Holland, D., Kiberd, B., Muirhead, N., Prasad, R., Tibbles, L. A., Treleaven, D., Fergusson, D. (2008). The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 23: 354-358 [Abstract] [Full Text]  
• Buchanan, P. M., Schnitzler, M. A., Brennan, D. C., Dzebisashvili, N., Willoughby, L. M., Axelrod, D., Salvalaggio, P. R., Abbott, K. C., Burroughs, T. E., Lentine, K. L. (2008). Novel Methods for Tracking Long-Term Maintenance Immunosuppression Regimens. CJASN 3: 117-124 [Abstract] [Full Text]  
• Villar, E., Chang, S. H., McDonald, S. P. (2007). Incidences, Treatments, Outcomes, and Sex Effect on Survival in Patients With End-Stage Renal Disease by Diabetes Status in Australia and New Zealand (1991 2005). Diabetes Care 30: 3070-3076 [Abstract] [Full Text]  
• Manns, B., Klarenbach, S., Lee, H., Culleton, B., Shrive, F., Tonelli, M. (2007). Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867-2878 [Abstract] [Full Text]  
• Verbeke, F., Van Biesen, W., Peeters, P., Van Bortel, L. M., Vanholder, R. C. (2007). Arterial stiffness and wave reflections in renal transplant recipients. Nephrol Dial Transplant 22: 3021-3027 [Abstract] [Full Text]  
• Nitsch, D., Burden, R., Steenkamp, R., Ansell, D., Byrne, C., Caskey, F., Roderick, P., Feest, T. (2007). Patients with diabetic nephropathy on renal replacement therapy in England and Wales. QJM 100: 551-560 [Abstract] [Full Text]  
• Gill, J. S., Hussain, S., Rose, C., Hariharan, S., Tonelli, M. (2007). Access to Kidney Transplantation among Patients Insured by the United States Department of Veterans Affairs. J. Am. Soc. Nephrol. 18: 2592-2599 [Abstract] [Full Text]  
• Djamali, A. (2007). Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am. J. Physiol. Renal Physiol. 293: F445-F455 [Abstract] [Full Text]  
• Villar, E., Remontet, L., Labeeuw, M., Ecochard, R., on behalf of the Association Regionale des Nephrol, (2007). Effect of Age, Gender, and Diabetes on Excess Death in End-Stage Renal Failure. J. Am. Soc. Nephrol. 18: 2125-2134 [Abstract] [Full Text]  
• Villar, E., Boissonnat, P., Sebbag, L., Hendawy, A., Cahen, R., Trolliet, P., Labeeuw, M., Ecochard, R., Pouteil-Noble, C. (2007). Poor prognosis of heart transplant patients with end-stage renal failure. Nephrol Dial Transplant 22: 1383-1389 [Abstract] [Full Text]  
• Johnston, O., Zalunardo, N., Rose, C., Gill, J. S. (2007). Prevention of Sepsis during the Transition to Dialysis May Improve the Survival of Transplant Failure Patients. J. Am. Soc. Nephrol. 18: 1331-1337 [Abstract] [Full Text]  
• Moreso, F., Grinyo, J. M. (2007). Graft dysfunction and cardiovascular risk--an unholy alliance. Nephrol Dial Transplant 22: 699-702 [Full Text]  
• Djamali, A., Sadowski, E. A., Muehrer, R. J., Reese, S., Smavatkul, C., Vidyasagar, A., Fain, S. B., Lipscomb, R. C., Hullett, D. H., Samaniego-Picota, M., Grist, T. M., Becker, B. N. (2007). BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. Am. J. Physiol. Renal Physiol. 292: F513-F522 [Abstract] [Full Text]  
• Valdes, C., Garcia-Mendoza, M., Rebollo, P., Ortega, T., Ortega, F. (2006). Mental health at the third month of haemodialysis as a predictor of short-term survival. Nephrol Dial Transplant 21: 3223-3230 [Abstract] [Full Text]  
• Matas, A. J. (2006). Why We Should Develop a Regulated System of Kidney Sales: A Call for Action!. CJASN 1: 1129-1132 [Full Text]  
• Bayat, S., Frimat, L., Thilly, N., Loos, C., Briancon, S., Kessler, M. (2006). Medical and non-medical determinants of access to renal transplant waiting list in a French community-based network of care. Nephrol Dial Transplant 21: 2900-2907 [Abstract] [Full Text]  
• Saracino, A., Santarsia, G., Latorraca, A., Gaudiano, V. (2006). Early assessment of renal resistance index after kidney transplant can help predict long-term renal function. Nephrol Dial Transplant 21: 2916-2920 [Abstract] [Full Text]  
• Robinson, B. M., Joffe, M. M., Pisoni, R. L., Port, F. K., Feldman, H. I. (2006). Revisiting Survival Differences by Race and Ethnicity among Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study. J. Am. Soc. Nephrol. 17: 2910-2918 [Abstract] [Full Text]  
• Dahm, F., Weber, M., Muller, B., Pradel, F. G., Laube, G. F., Neuhaus, T. J., Cao, C., Wuthrich, R. P., Thiel, G. T., Clavien, P.-A. (2006). Open and laparoscopic living donor nephrectomy in Switzerland: a retrospective assessment of clinical outcomes and the motivation to donate. Nephrol Dial Transplant 21: 2563-2568 [Abstract] [Full Text]  
• Tonelli, M., Klarenbach, S., Manns, B., Culleton, B., Hemmelgarn, B., Bertazzon, S., Wiebe, N., Gill, J. S., for the Alberta Kidney Disease Network, (2006). Residence location and likelihood of kidney transplantation.. CMAJ 175: 478-482 [Abstract] [Full Text]  
• Kaufman, S. R., Shim, J. K., Russ, A. J. (2006). Old age, life extension, and the character of medical choice.. Journals of Gerontology Series B: Psychological Sciences and Social Science 61: S175-S184 [Abstract] [Full Text]  
• Chandrakantan, A., de Mattos, A. M., Naftel, D., Crosswy, A., Kirklin, J., Curtis, J. J. (2006). Increasing Referral for Renal Transplant Evaluation in Recipients of Nonrenal Solid-Organ Transplants: A Single-Center Experience. CJASN 1: 832-836 [Abstract] [Full Text]  
• Djamali, A., Samaniego, M., Muth, B., Muehrer, R., Hofmann, R. M., Pirsch, J., Howard, A., Mourad, G., Becker, B. N. (2006). Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. CJASN 1: 623-640 [Abstract] [Full Text]  
• Nishi, H., Hanafusa, N., Kondo, Y., Nangaku, M., Sugawara, Y., Makuuchi, M., Noiri, E., Fujita, T. (2006). Clinical Outcome of Thrombotic Microangiopathy after Living-Donor Liver Transplantation Treated with Plasma Exchange Therapy. CJASN 1: 811-819 [Abstract] [Full Text]  
• Sprangers, B., Waer, M., Billiau, A. D. (2006). Xenograft rejection--all that glitters is not Gal. Nephrol Dial Transplant 21: 1486-1488 [Full Text]  
• Geddes, C. C, Rodger, R S. C (2006). Kidneys for transplant. BMJ 332: 1105-1106 [Full Text]  
• Schold, J. D., Meier-Kriesche, H.-U. (2006). Which Renal Transplant Candidates Should Accept Marginal Kidneys in Exchange for a Shorter Waiting Time on Dialysis?. CJASN 1: 532-538 [Abstract] [Full Text]  
• Hoffman, F. M., Nelson, B. J., Drangstveit, M. B., Flynn, B. M., Watercott, E. A., Zirbes, J. M. (2006). Caring for Transplant Recipients in a Nontransplant Setting. Crit Care Nurse 26: 53-73 [Full Text]  
• Geddes, C. C., van Dijk, P. C. W., McArthur, S., Metcalfe, W., Jager, K. J., Zwinderman, A. H., Mooney, M., Fox, J. G., Simpson, K. (2006). The ERA-EDTA cohort study--comparison of methods to predict survival on renal replacement therapy. Nephrol Dial Transplant 21: 945-956 [Abstract] [Full Text]  
• Bozbas, H., Yildirir, A., Muderrisoglu, H. (2006). Cardiac enzymes, renal failure and renal transplantation.. Clin Med Res 4: 79-84 [Abstract] [Full Text]  
• Delmonico, F. L., Burdick, J. F. (2006). Maximizing the Success of Transplantation with Kidneys from Older Donors. NEJM 354: 411-413 [Full Text]  
• Becker, B. N., Rush, S. H., Dykstra, D. M., Becker, Y. T., Port, F. K. (2006). Preemptive Transplantation for Patients With Diabetes-Related Kidney Disease. Arch Intern Med 166: 44-48 [Abstract] [Full Text]  
• Kandus, A., Arnol, M., Bren, A. F. (2006). Renal transplantation in Slovenia after joining Eurotransplant. Nephrol Dial Transplant 21: 36-39 [Abstract] [Full Text]  
• Merion, R. M., Ashby, V. B., Wolfe, R. A., Distant, D. A., Hulbert-Shearon, T. E., Metzger, R. A., Ojo, A. O., Port, F. K. (2005). Deceased-Donor Characteristics and the Survival Benefit of Kidney Transplantation. JAMA 294: 2726-2733 [Abstract] [Full Text]  
• Knoll, G., Cockfield, S., Blydt-Hansen, T., Baran, D., Kiberd, B., Landsberg, D., Rush, D., Cole, E., for The Kidney Transplant Working Group of the Can, (2005). Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ 173: S1-S25 [Full Text]